GlassScriptPhysician profile
Ronald Ira Waloff
NPI 1770547465
$3,552.10
in general payments reported to CMS, 2019-2025
23 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $401 · 2021: $494 · 2022: $422 · 2023: $414 · 2024: $371 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.14 |
| Education | $112.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.20 | 2019-2024 | Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $485.29 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $455.73 | 2020-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $385.85 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Madrigal Pharmaceuticals | $193.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $189.40 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $125.01 | 2023 | |
| Daiichi Sankyo INC. | $121.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $112.18 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $100.58 | 2019-2023 | Ocaliva |
| Shionogi INC | $94.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $90.23 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $89.76 | 2021-2025 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $89.71 | 2019-2023 | Entyvio |
| Medivators INC. | $67.83 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $59.71 | 2023 | Zeposia |
| Celgene Corporation | $59.12 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $48.31 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $34.17 | 2020 | |
| Allergan, INC. | $32.63 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $20.60 | 2020 | |
| Axonics, INC. | $12.85 | 2020 | |
| Redhill Biopharma INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Waloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.